DMAC - NASDAQ
DiaMedica Therapeutics Inc.
$5.70
-1.2%DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
At a Glance
Live SnapshotDiaMedica Therapeutics Inc. Fair Value Envelope
Owner Earnings Valuation Tool
Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation
Historical Financial Data
Base year metrics used for projections
Projection Settings
Forecast period and terminal assumptions
DCF Valuation Summary
Calculation flow from present value to intrinsic value per share
Owner Earnings Projections
Operating Cash Flow - Maintenance CapEx = Owner Earnings
| Metric | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | Year 6 | Year 7 | Year 8 | Year 9 | Year 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$19.9M | -$13.6M | -$9.3M | -$6.3M | -$4.3M | -$3.0M | -$2.0M | -$1.4M | -$942.8K | -$644.1K |
| Maintenance CapEx | -$5.5K | -$3.7K | -$2.6K | -$1.7K | -$1.2K | -$814 | -$556 | -$380 | -$260 | -$177 |
| Owner Earnings | -$19.9M | -$13.6M | -$9.3M | -$6.3M | -$4.3M | -$3.0M | -$2.0M | -$1.4M | -$943.0K | -$644.3K |
| Discount Factor | 0.926 | 0.857 | 0.794 | 0.735 | 0.681 | 0.630 | 0.583 | 0.540 | 0.500 | 0.463 |
| Present Value | -$18.4M | -$11.6M | -$7.4M | -$4.7M | -$2.9M | -$1.9M | -$1.2M | -$745.7K | -$471.8K | -$298.4K |
Related Guides
Continue your DMAC research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.